Characteristics of the response to treatment in outpatients with the first episode of schizophrenia spectrum disorders

Egor  Chumakov; Natalia  Petrova; Oleg   Limankin

doi:10.21638/spbu11.2019.304

Авторы

Egor Chumakov St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation https://orcid.org/0000-0002-0429-8460
Natalia Petrova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation https://orcid.org/0000-0003-4096-6208
Oleg Limankin St. Petersburg Psychiatric Hospital №1 named after P. P. Kaschenko, 12, Kanonerskaya ul., St. Petersburg, 190121, Russian Federation ; St. Petersburg Institute of Postgraduate Improvement of Physicians-experts of the Ministry of Labour and Social Protection, 11/12, Bolshoy Sampsonievskiy pr., St. Petersburg, 194044, Russian Federation ;North-Western State Medical University named after I. I. Mechnikov, 41, Kirochnaya ul., St. Petersburg, 191015, Russian Federation https://orcid.org/0000-0001-6318-7536

DOI:

https://doi.org/10.21638/spbu11.2019.304

Аннотация

Identifying predictors of treatment response in patients with the first episode of schizophrenia spectrum disorders is an important issue in the field. The objective of the study was to assess the incidence of poor response to treatment and the factors that influence it in outpatients with the first episode of schizophrenia spectrum disorders. Medical records of the outpatients seeking treatment in 2017 in 3 day inpatient departments of the two districts in St. Petersburg, Russia, were examined. 73 patients diagnosed with schizophrenia spectrum disorders (ICD-10) met the criteria for the first episode (the duration of the disease is up to 5 years, the number of episodes is not more than three) and made up the study group. It has been established that up to 49 % of outpatients with the first episode of schizophrenia spectrum disorders were characterized by poor responses to antipsychotic therapy during outpatient treatment. Factors predicting a poor response to therapy may include earlier onset of illness, concomitant brain damage, and low adherence to therapy.

Ключевые слова:

schizophrenia, schizophrenia spectrum disorders, first episode, treatment response, outpatients

Скачивания

Данные скачивания пока недоступны.

Библиографические ссылки

References

Jager M., Riedel M., Messer T., Laux G., Pfeiffer H., Schmidt D. N. L., Gaebel W., Huff W., Heuser I., Lemke K.-U. K. M., Ruther E., Buchkremer G., Gastpar M., Bottlender R., Strauß A., Moller H.-J. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci., 2007, vol. 257, iss. 1, pp. 47–53.

Robinson D. G., Woerner M. G., Delman H. M., Kane J. M. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull., 2005, vol. 31, iss. 3, pp. 705–722. https://doi.org/10.1093/schbul/sbi032.

Dixon L. B., Stroup T. S. Medications for first-episode psychosis: making a good start. Am. J. Psychiatry., 2015, vol. 172, iss. 3, pp. 209–211. https://doi.org/10.1176/appi.ajp.2014.14111465.

Ohlsen R. I., O’Toole M. S., Purvis R. G., Walters J. T., Taylor T. M., Jones H. M., Pilowsky L. S. Clinical effectiveness in first episode patients.Eur Neuropsychopharamacol., 2004, Suppl 4, S445–S451. https://doi.org/10.1016/j.euroneuro.2004.08.003.

Chiliza B., Asmal L., Kilian S., Phahladira L., Emsley R. Rate and predictors of non-response to first line antipsychotic treatment in first-episode schizophrenia. Hum Psychopharmacol., 2015, vol. 30,iss. 3, pp. 173–82. https://doi.org/10.1002/hup.2469.

Sanger T. M., Lieberman J. A., Tohen M., Grundy S., Beasley C. Jr., Tollefson G. D. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry., 1999, vol. 156, iss. 1, pp. 79–87.https://doi.org/10.1176/ajp.156.1.79.

Harvey P. D., Rosenthal J. B. Treatment resistant schizophrenia: course of brain structure and function. Prog Neuropsychopharmacol Biol Psychiatry., 2016, vol. 70, pp. 111–116. https://doi.org/10.1016/j.pnpbp.2016.02.008.

Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry.,1993, vol. 50, iss. 5, pp. 369–376.

Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J. M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta analysis. Lancet,2012, vol. 379, pp. 2063–2071. https://doi.org/10.1016/S0140-6736(12)60239-6.

Perkins D. O., Gu H., Boteva K., Lieberman J. A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry., 2005, vol. 162, iss. 10, pp. 1785–1804. https://doi.org/10.1176/appi.ajp.162.10.1785.

Oosthuizen P., Emsley R. A., Keyter N., Niehaus D. J., Koen L. Duration of untreated psychosis and outcome in first episode psychosis. Perspective from a developing country. Acta Psychiatr Scand., 2005, vol. 111, iss. 3, pp. 214–219. https://doi.org/10.1111/j.1600-0447.2004.00448.x.

Strauss G. P., Vertinski M., Vogel S. J., Ringdahl E. N., Allen D. N. Negative symptoms in bipolar disorder and schizophrenia: A psychometric evaluation of the brief negative symptom scale across diagnostic categories.Schizophr Res., 2016, vol. 170, iss. 2–3, pp. 285–289. https://doi.org/10.1016/j.schres.2015.12.014.

Patel R., Wilson R., Jackson R., Ball M., Shetty H., Broadbent M., Stewart R., McGuire P., Bhattacharyya S. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open., 2016, vol. 6, iss. 3. https:/doi.org/10.1136/bmjopen-2015-009888.

Martinuzzi E., Barbosa S., Daoudlarian D., Bel Haj Ali W., Gilet C., Fillatre L., Khalfallah O., Troudet R., Jamain S., Fond G., Sommer I., Leucht S., Dazzan P., McGuire P., Arango C., Diaz-Caneja C. M., Fleischhacker W., Rujescu D., Glenthu B., Winter I., Kahn R. S., Yolken R., Lewis S., Drake R., Davidovic L., Leboyer M., Glaichenhaus N. OPTiMiSE Study Group. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry., 2019, vol. 9, iss. 1. https://doi.org/10.1038/s41398-018-0366-5.

Zhu Y., Krause M., Huhn M., Rothe P., Schneider-Thoma J., Chaimani A., Li C., Davis J. M., Leucht S. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry., 2017, vol. 4, pp. 694–705.https://doi.org/10.1016/S2215-0366(17)30270-5.

Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H. J. German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia — maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the german research network on schizophrenia. J. Clin Psychiatry.,2011, vol. 72, iss. 2, pp. 205–218. https://doi.org/10.4088/JCP.09m05459yel.

Correll C. U., Galling B., Pawar A., Krivko A., Bonetto C., Ruggeri M., Craig T. J., Nordentoft M., Srihari V. H., Guloksuz S., Hui C. L. M., Chen E. Y. H., Valencia M., Juarez F., Robinson D. G., Schooler N. R., Brunette M. F., Mueser K. T., Rosenheck R. A., Marcy P., Addington J., Estroff S. E., Robinson J., Penn D., Severe J. B., Kane J. M. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry., 2018,vol. 75, iss. 6, pp. 555–565. https://doi.org/10.1001/jamapsychiatry.2018.0623.

Abdel-Baki A., Ouellet-Plamondon C., Malla A. Pharmacotherapy challenges in patients with first-episode psychosis.J Affect Disord., 2012, vol. 138, Suppl, S3–14. https://doi.org/10.1016/j.jad.2012.02.029.

Mayoral-van Son J., de la Foz V. O., Martinez-Garcia O., Moreno T., Parrilla-Escobar M., Valdizan E. M., Crespo-Facorro B. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J. Clin. Psychiatry., 2016, vol. 77, iss. 4, pp. 492–500. https://doi.org/10.4088/JCP.14m09540.

Ayesa-Arriola R., Morinigo J. D., David A. S., Perez-Iglesias R., Rodrıguez-Sanchez J. M.,Crespo-Facorro B. Lack of insight 3 years after first-episode psychosis: an unchangeable illness trait determined from first presentation? Schizophr Res., 2014, vol. 157, iss. 1–3, pp. 271–277. https://doi.org/10.1016/j.schres.2014.05.011.

Zipursky R. B., Menezes N. M., Streiner D. L. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review.Schizophr Res., 2014, vol. 152, iss. 2-3,pp. 408–414. https://doi.org/10.1016/j.schres.2013.08.001.

García S., Martínez-Cengotitabengoa M., López-Zurbano S., Zorrilla I., López P., Vieta E.,González-Pinto A. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol., 2016, vol. 36, iss. 4, pp. 355–371. https://doi.org/10.1097/JCP.0000000000000523.

Jeong H. G., Lee M. S. Long-acting Injectable Antipsychotics in First-episode Schizophrenia. Clin Psychopharmacol Neurosci., 2013, vol. 11, iss. 1, pp. 1-6. https://doi.org/10.9758/cpn.2013.11.1.1.

Kanahara N., Hiroshi Y., Suzuki T., Takase M., Iyo M. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. BMC Psychiatry., 2018, vol. 18. https://doi.org/10.1186/s12888-018-1853-1.

van Os J., Kapur S. Schizophrenia. Lancet., 2009, vol. 374, iss. 9690, pp. 635–645. https://doi.org/10.1016/S0140-6736(09)60995-8.

Lally J., Ajnakina O., Stubbs B., Cullinane M., Murphy K. C.,Gaughran F., Murray R. M. Remission and recovery from first-episode psychosis in adults: systematic review and metaanalysis of long-term outcome studies. Br J Psychiatry., 2017, vol. 211, iss. 6, pp. 350–358. https://doi.org/10.1192/bjp.bp.117.201475.

Jaaskelainen E., Juola P., Hirvonen N., McGrath J. J., Saha S., Isohanni M., Veijola J., Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull., 2013, vol. 39,iss. 6, pp. 1296–1306. https://doi.org/10.1093/schbul/sbs130.

Downs J., Dean H., Lechler S., Sears N., Patel R., Shetty H., Hotopf M., Ford T., Kyriakopoulos M., Diaz-Caneja C. M., Arango C., MacCabe J. H., Hayes R. D., Pina-Camacho L. Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure.Schizophr Bull.,2019, vol. 45, iss. 1, pp. 69–79. https://doi.org/10.1093/schbul/sbx197.

Penttilä M., Jääskeläinen E., Hirvonen N., Isohanni M., Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry., 2014, vol. 205, iss. 2, pp. 88–94. https://doi.org/10.1192/bjp.bp.113.127753.

Demjaha A., Lappin J. M., Stahl D., Patel M. X., MacCabe J. H., Howes O. D., Heslin M., Reininghaus U. A., Donoghue K., Lomas B., Charalambides M., Onyejiaka A., Fearon P., Jones P., Doody G., Morgan C., Dazzan P., Murray R. M. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med., 2017, vol. 47, iss. 11, pp. 1981–1989. https://doi.org/10.1017/S0033291717000435.